Obesity Clinical Trial
Official title:
Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss II (MIPS II)
The obesity epidemic has grown rapidly in the United States, and is associated with increased morbidity and mortality rates. Bariatric surgery (BS) has emerged as the most effective treatment for severe obesity. Surgical weight loss (WL) is very significant (~40-50kg) during the first 6-12 months after surgery. The adequate amount of dietary protein during the active period of surgical weight loss is not known. Dietary protein affects body weight regulation: satiety, thermogenesis, energy efficiency and body composition. During diet-induced energy-restriction, sustaining protein intake (PI) at the level of requirement (0.8g /kg ideal body weight (IBW)/ day) appears to preserve fat free mass (FFM) during active WL. PI above requirements (1.2g protein/Kg IBW/ day) results in favorable body composition changes, with greater decrease in fat mass and preservation of FFM, but without effecting WL. Dietary PI 0.8g/day has been associated with greater satiety and increased energy expenditure (EE) during calorie restriction. In this randomized prospective study, the investigators will evaluate the effect of PI on nitrogen balance, body composition, EE and satiety in 40 women undergoing either Gastric Bypass or Vertical Sleeve Gastrectomy, assigned to high protein supplementation (PRO-S), high PRO-S (1.2g /kg IBW/day) or standard- based current guidelines -PRO-S (0.8g /kg IBW/day). PRO-S will be supplied for 3 months after surgery. Outcome measures including nitrogen balance, body composition changes and satiety will be assessed at pre-surgery, and at 3, 6 and 12 months post-surgery. These results will help provide evidence-based data on safe and optimal levels of protein supplementation after BS
The goal of this proposal is to study the effect of dietary protein supplementation (PRO-S)
during surgical weight loss, on nitrogen balance, energy expenditure, body composition of
weight loss, and satiety. The overall goal is to provide evidence-based data on optimal
levels of protein supplementation after surgical weight loss by gastric bypass (GBP), a
restrictive and malabsorptive procedure, or by vertical sleeve gastrectomy (VSG), a purely
restrictive procedure.
We propose a prospective randomized controlled trial (RCT), in which, patients undergoing
either GBP or VSG will be allocated to standard PRO-S recommendation ("standard care"
according to the American Society for Metabolic and Bariatric Surgery Guidelines) or high
supplementation. We will compare 4 groups of subjects:
- Group 1: GBP Standard PRO-S (0.8g protein/kg ideal body weight (IBW)/day
- Group 2: GBP High PRO-S (1.2g protein/ kg ideal body weight (IBW)/ day)
- Group 3: VSG Standard PRO-S (0.8g protein/kg ideal body weight (IBW)/day
- Group 4: VSG High PRO-S (1.2g protein/ kg ideal body weight (IBW)/ day)
AIM#1: Measure total body nitrogen balance (NB) to assess adequacy of levels of protein
intake and protein absorption.
AIM#2: Measure the effect PRO-S on lean body mass (LBM), and resting energy expenditure
(REE).
AIM#3: Measure the effect of PRO-S on satiety. Hypothesis 3.1: Patients in the High PRO-S
group will experience higher levels of perceived satiety compared with patients in the
standard PRO-S group.
AIM #4: Study adherence to protein supplementation. Hypothesis : Adherence will be greater in
the Standard PRO-S group.
Background and Significance The obesity epidemic has grown rapidly in the United States, and
is associated with increased morbidity and mortality rates. Although preventive measures are
needed to solve the obesity epidemic in the long-term, bariatric surgery has become a popular
and effective treatment of severe obesity. Obesity and its co-morbidities, including type 2
diabetes (T2DM), have a high health care cost2. The cost is even greater for severe obesity
(BMI≥40 kg/m2).
Protein (PRO) malnutrition after bariatric surgery (BS) Bariatric surgery (BS) has emerged as
the most effective treatment for severe obesity. Gastric bypass surgery (GBP) results in
large weight loss with normalization of metabolic functions, including T2DM remission in
~60-80% of cases. Weight loss is very significant (~40-50kg). The rate of weight loss is
rapid during the first year after surgery. Surgical weight loss can be associated with
vitamin, mineral, and protein deficiencies. PRO malnutrition, remains the most severe
nutritional complication associated with malabsorptive surgical procedures. The prevalence of
protein malnutrition after malabsorptive BS procedures varies between 3 to 18% and is
associated with the length of the bypassed segment. The US recommended dietary allowance
(RDA) for protein is ~50 g/d for healthy normal weight adults. Experts and clinicians
recommend ~70 g/d of protein during low-calorie diets or 60 g/day (standard) and 120 g/day
(high) in the earlier months after BS. However, there is little evidence-based data to
support these recommendations. In spite of the absence of level 1 data on types and amount of
protein recommendations, the American Society for Metabolic Surgery and BS's website has 14
links for commercial nutrition supplements14. In this study, we aim to study protein
absorption and adequacy of protein intake by nitrogen balance in patients following standard
and high PRO-S following BS.
Effects of dietary proteins Dietary PRO-S and amino acids (AA) are important modulators of
body weight by affecting various determinants of body weight regulation: satiety,
thermogenesis, energy efficiency and body composition. During energy restriction, sustaining
protein intake at the level of requirement (0.8g protein/kg ideal body weight (IBW)/ day)
appears to be sufficient to induce body weight loss while preserving fat free mass (FFM).
Protein intake above requirements (1.2g protein/Kg IBW/ day) results in a greater decrease in
fat mass and preservation of FFM, but has no effect on body weight loss.
Nitrogen balance (NB) study The NB method is classically used to determine adequate protein
intakes and to measure whole body protein balance in response to nutritional interventions.
Prolonged negative nitrogen balance should not be sustained for long periods due its negative
impact on overall health.
Risk of decreased lean body mass (LBM) and resting energy expenditure (REE) with surgical
weight loss BS results in large weight losses (30-50kg), with both fat mass (FML) and LBM
losses. Our previous observational studies aiming to evaluate the relationship between
protein intake and loss of LBM following BS have shown that protein intake > 60g/ day is
associated with better maintenance of LBM after BS. LBM is the main determinant of REE,
explaining 75% of the REE variance with REE being the largest component of 24-h energy
expenditure (EE). Reduced EE may trigger weight regain in this population. High PRO-S diets
may also benefit this population by increasing EE while preventing LBM loss. Increased EE
from dietary protein is attributed to an enhanced thermic effect (23-30%) compared to
carbohydrates (5-10%) or lipids (2-3%).
Dietary protein intake and satiety High-protein intake increases satiety despite energy
restriction. Proposed mechanisms are as follows: a ketogenic state, relatively elevated
plasma amino acid (AA) levels, and anorexigenic hormone concentrations feedback on the
central nervous system to prolong the duration before one feels hunger for the next meal
(satiety) such as, Peptide YY, Glucagon-Like Peptide -1 and cholecystokinin produced in
response to peripheral and central detection of amino acid, and decreased levels of the
orexigenic hormone ghrelin.
Protein supplementation and adherence Low protein intake after BS has been reported. PRO-S
has always been recommended after BS but its feasibility has not been well addressed in any
RCT. We will study adherence to PRO-S. Increasing adherence with dietary recommendation is
challenging, but may represent a key strategy to improve the clinical nutritional treatment
and outcomes after BS.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |